Skip to main content
. 2019 May;25(5):10.18553/jmcp.2019.25.5.510. doi: 10.18553/jmcp.2019.25.5.510

TABLE 1.

Biologic Therapies for Asthma with Type 2 Inflammation

Drug FDA Indication Dosing Mechanism
Omalizumab (Xolair, Genentech) Aged ≥ 6 years with moderate to severe persistent asthma who test positive for year-round allergens14 75-375 mg SC Q 2-4 weeks Anti-IgE
Mepolizumab (Nucala, GlaxoSmithKline) Aged ≥ 12 years with severe asthma and eosinophilic phenotype15 100 mg SC Q 4 weeks Anti-IL-5
Reslizumab (Cinqair, Teva) Aged ≥ 18 years with severe asthma and eosinophilic phenotype16 3 mg/kg IV Q 4 weeks Anti-IL-5
Benralizumab (Fasenra, AstraZeneca) Aged ≥ 12 years with severe asthma and eosinophilic phenotype17 30 mg SC Q 4 weeks × 3, then Q 8 weeks Anti-IL-5Ra
Dupilumab (Dupixent, Sanofi/Regeneron) Aged ≥ 12 years with moderate to severe asthma with eosinophilic phenotype or with oral corticosteroid-dependent asthma18 200 mg SC Q 2 weeks 300 mg SC Q 2 weeks Anti-IL-4Ra

FDA = U.S. Food and Drug Administration; IgE = immunoglobin E; IL-4Ra = interleukin-4 receptor alpha; IL-5 = interleukin-5; IL-5Ra = interleukin-5 receptor alpha; IV = intravenous; Q = every; SC = subcutaneous.